| First-line treatment of HER2-positive metastatic breast cancer with dual blockade including biosimilar trastuzumab (SB3): population-based real-world data from the DBCG A Celik, T Berg, LB Nielsen, MB Jensen, B Ejlertsen, A Knoop, ... Breast Cancer: Basic and Clinical Research 16, 11782234221086992, 2022 | 8 | 2022 |
| Real-World Survival and Treatment Regimens Across First-to Third-Line Treatment for Advanced Triple-Negative Breast Cancer A Celik, T Berg, MB Jensen, E Jakobsen, HM Nielsen, I Kümler, V Glavicic, ... Breast Cancer: Basic and Clinical Research 17, 11782234231203292, 2023 | 3 | 2023 |
| Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer: a nationwide, retrospective study A Celik, T Berg, M Gibson, MB Jensen, I Kümler, S Eßer-Naumann, ... Acta oncologica (Stockholm, Sweden) 63, 494-502, 2024 | | 2024 |
| Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study T Berg, MB Jensen, A Celik, ML Talman, MA Misiakou, AS Knoop, ... JCI insight 9 (7), 2024 | | 2024 |
| Real-world survival of Danish patients with HER2-positive metastatic breast cancer D Artzi, T Berg, A Celik, I Kümler, J Kenholm, S Al-Rawi, MB Jensen, ... Acta Oncologica 62 (6), 601-607, 2023 | | 2023 |
| Targeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly A Celik, T Berg, AS Knoop, M Andersson Ugeskrift for Laeger 183 (26), V12200938-V12200938, 2021 | | 2021 |
